Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 USD | +6.45% | +4.76% | +2.48% |
01:31pm | HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target | MT |
03-08 | Ovid Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Evolution of the average Target Price on Ovid Therapeutics Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Ovid Therapeutics Inc.
BTIG | |
Oppenheimer | |
JonesTrading Institutional Services | |
Citigroup | |
Cantor Fitzgerald |
EPS Revisions
- Stock Market
- Equities
- OVID Stock
- Consensus Ovid Therapeutics Inc.